Exosomes are small membrane-enclosed vesicles, typically 30 to 150 nanometers in diameter, that are released by virtually all cell types and carry a cargo of proteins, lipids, and nucleic acids including mRNAs, microRNAs, and long non-coding RNAs. Cancer cells shed exosomes into the bloodstream and other body fluids at elevated rates, and the molecular content of these vesicles reflects the biology of the tumor cells that produced them.
This makes exosomes highly attractive as a source of liquid biopsy biomarkers for pancreatic ductal adenocarcinoma (PDAC), a cancer where conventional tissue biopsy can be technically challenging and where early detection is desperately needed. Unlike circulating tumor DNA, exosomes carry a diverse cargo that includes functional proteins and regulatory RNAs, potentially providing richer biological information.
However, the pancreatic cancer exosome transcriptome and proteome are not fully characterized, and it is unclear which exosomal genes and transcripts are most relevant as diagnostic or therapeutic targets. This study used a systematic bioinformatics approach to mine public databases and identify the most promising exosomal gene targets for PDAC.
The researchers used a multi-database mining strategy centered on ExoCarta, a curated public database of experimentally validated exosomal contents from multiple cell types and diseases. ExoCarta catalogs the proteins, lipids, and nucleic acids identified in exosomes across hundreds of published studies, providing a systematic resource for identifying exosomal components.
Candidate genes identified from ExoCarta were cross-referenced against GeneCards and VarElect, tools that provide comprehensive gene annotation and disease-gene association data respectively. This cross-referencing allowed the team to prioritize genes with documented relevance to cancer biology, known involvement in PDAC-specific pathways, or associations with prognosis in pancreatic cancer.
The analysis explicitly distinguished between protein-coding genes, non-coding RNA genes (including microRNAs and long non-coding RNAs), and open reading frames (ORFs), recognizing that each class plays distinct biological roles and may have different utility as biomarkers or drug targets.
The analysis identified 22 protein-coding genes as high-priority exosomal targets with relevance to PDAC. These genes are present in cancer cell-derived exosomes and have documented functions in processes central to PDAC biology, including cell proliferation, invasion, immune evasion, and metabolic reprogramming.
Importantly, seven of the 22 protein-coding targets were found to be the molecular targets of FDA-approved drugs, meaning that existing therapeutic agents already modulate these proteins. This overlap between exosomal PDAC-relevant proteins and current drug targets suggests that some of these agents might be candidates for repurposing or for monitoring treatment response through exosomal biomarker analysis.
Functional pathway analysis of the 22 protein-coding genes revealed enrichment in signaling pathways commonly dysregulated in pancreatic cancer, including EGFR, KRAS, PI3K/AKT, and cell cycle control pathways. This functional clustering supports the biological plausibility of these targets and provides a basis for understanding how they might contribute to PDAC progression and therapeutic resistance.
Beyond protein-coding genes, the analysis identified 26 non-coding RNA (ncRNA) genes present in pancreatic cancer exosomes with relevance to PDAC. These include both microRNAs (miRNAs), which post-transcriptionally repress gene expression by binding to target mRNAs, and long non-coding RNAs (lncRNAs), which regulate gene expression through diverse mechanisms including chromatin remodeling and protein scaffolding.
Several of the identified miRNAs have been previously linked to PDAC in the literature, including roles in regulating apoptosis resistance, cancer stem cell properties, and metastatic behavior. The lncRNAs identified include some that have been reported to promote PDAC growth or to regulate the tumor microenvironment, providing additional mechanistic context for their relevance as targets.
Additionally, 9 open reading frames (ORFs) were identified in pancreatic cancer exosomes. ORFs represent genomic sequences with the potential to encode proteins but which have not been fully characterized at the functional level. These candidates merit further experimental investigation as potential novel biomarkers or as previously unrecognized contributors to PDAC biology.
The identification of FDA-approved drug targets among the exosomal protein-coding genes opens a practical near-term avenue for clinical investigation. Drugs already approved for other cancers could potentially be evaluated in PDAC through biomarker-stratified trials where patients are selected based on exosomal expression of the relevant target gene, leveraging the liquid biopsy nature of exosomal analysis to make patient selection feasible without requiring repeated tissue biopsies.
The exosomal ncRNAs identified in this study are particularly attractive as diagnostic biomarkers. miRNAs are highly stable in biofluids, resistant to degradation, and amenable to sensitive quantification by qPCR and next-generation sequencing. A plasma-based panel combining multiple exosomal miRNAs might achieve the sensitivity and specificity needed for early PDAC detection in high-risk populations.
Exosomal cargo also reflects the current state of tumor biology in a way that static genomic analysis cannot, since exosome composition changes as tumors evolve under treatment pressure. This means exosomal monitoring could be used for treatment response assessment and early detection of acquired resistance, providing actionable information to guide therapy adjustments.
The study also noted the presence of pseudogenes among exosomal RNA transcripts. Pseudogenes are genomic sequences that resemble protein-coding genes but have accumulated mutations that prevent translation into functional protein. Historically dismissed as genomic debris, pseudogene transcripts have recently been recognized as functional regulators of their parent genes through competing endogenous RNA (ceRNA) mechanisms.
In the ceRNA model, pseudogene transcripts act as molecular sponges that bind and sequester miRNAs, reducing the availability of those miRNAs to suppress their target mRNAs. This can effectively derepress oncogenes that are normally held in check by those miRNAs, providing a non-mutational mechanism for altering gene expression in cancer cells.
The presence of pseudogene transcripts in pancreatic cancer exosomes adds another layer of complexity to the regulatory landscape of PDAC and suggests that comprehensive characterization of the exosomal transcriptome, beyond protein-coding genes alone, will be necessary to fully understand how exosomes contribute to the systemic biology of this disease.
This bioinformatics study provides the first systematic catalog of exosomal gene targets with documented relevance to pancreatic cancer, integrating protein-coding genes, ncRNAs, pseudogenes, and ORFs into a unified resource for researchers in the field. The identification of 22 protein-coding targets, 26 ncRNAs, and 9 ORFs substantially expands the set of candidates available for experimental validation.
The next steps for translating these findings require experimental validation in cell culture and animal models to confirm that the identified exosomal genes are functionally important in PDAC biology, followed by clinical studies measuring their expression in plasma exosomes from PDAC patients compared to healthy controls and patients with benign pancreatic disease.
If validated, a subset of these exosomal gene targets could form the basis of a blood test for early PDAC detection, a therapeutic target for antibody or small molecule drug development, or a pharmacodynamic biomarker for monitoring drug activity in clinical trials. This study lays the groundwork for that translational research program.